AUM $153.6MER 0.50%NAV $54.37Holdings 103Inception Dec 2014
Price Chart
Key Statistics
Previous Close
$53.54Day Range
$52.64$53.50
52-Week Range
$27.22$57.67
Avg Volume
50.9KDividend Yield
2.29%Expense Ratio
0.50%AUM
$153.6MShares Outstanding
2.5METF Grades
?ETF Grades compare this fund against others in the same category using percentile rankings across six factors. Grades range from A+ (top 5%) to F (bottom 20%). Updated daily.Sector Breakdown
| Sector | Weight % |
|---|---|
| Healthcare | 100.00% |
Country Allocation
| Country | Weight % |
|---|---|
| United States | 84.00% |
| Ireland | 3.33% |
| Netherlands | 3.15% |
| Canada | 2.76% |
| Switzerland | 1.65% |
| China | 1.53% |
| Belgium | 1.13% |
| United Kingdom | 1.04% |
| Germany | 0.91% |
| Cayman Islands | 0.50% |
Fund Information
- Issuer
- ALPS Funds
- Category
- Healthcare
- Types
- Healthcare
- Inception Date
- Dec 30, 2014
- Exchange
- NYSE_ARCA
- Description
- The ALPS Medical Breakthroughs ETF (SBIO) seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI).
Similar ETFs
The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund issued by ALPS Funds that launched on Dec 30, 2014. It currently manages $153.6M in assets under management. The fund charges an expense ratio of 0.50%. The fund holds 103 securities in its portfolio. It falls under the Healthcare category.
Top 10 holdings represent 32.4% of the fund
| Rank | Symbol | Name | Weight % | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc. | 4.16% | 75,290 | $6.4M |
| 2 | CGON | CG oncology Inc. | 3.48% | 77,868 | $5.3M |
| 3 | CELC | Celcuity Inc. | 3.36% | 42,674 | $5.2M |
| 4 | ALKS | Alkermes PLC | 3.33% | 153,685 | $5.1M |
| 5 | MIRM | Mirum Pharmaceuticals Inc. | 3.31% | 55,644 | $5.1M |
| 6 | SYRE | Spyre Therapeutics Inc. | 3.28% | 72,432 | $5.0M |
| 7 | APLS | Apellis Pharmaceuticals Inc. | 3.14% | 117,885 | $4.8M |
| 8 | APGE | Apogee Therapeutics Inc. | 2.88% | 51,642 | $4.4M |
| 9 | XENE | Xenon Pharmaceuticals Inc. | 2.76% | 76,719 | $4.2M |
| 10 | FOLD | Amicus Therapeutics Inc. | 2.73% | 289,567 | $4.2M |
| 11 | CRNX | Crinetics Pharmaceuticals Inc. | 2.41% | 96,556 | $3.7M |
| 12 | DNTH | Dianthus Therapeutics Inc. | 2.33% | 41,012 | $3.6M |
| 13 | VKTX | Viking Therapeutics Inc. | 2.27% | 106,565 | $3.5M |
| 14 | ACAD | ACADIA Pharmaceuticals Inc. | 2.25% | 157,227 | $3.5M |
| 15 | TVTX | Travere Therapeutics Inc. | 2.24% | 85,067 | $3.4M |
Page 1 of 3
Detailed Returns
| Period | Return | ETF |
|---|---|---|
| 1D | -1.03% | |
| 1W | -5.15% | |
| 1M | +10.27% | |
| 3M | +1.20% | |
| 6M | +17.40% | |
| YTD | +5.64% | |
| 1Y | +81.53% | |
| 3Y | +73.12% | |
| 5Y | +5.73% |
Moving Averages
20-Day MA
$54.83
Below 20-Day MA50-Day MA
$52.08
Above 50-Day MA200-Day MA
$44.96
Above 200-Day MAPrice with Moving Averages
Support & Resistance
52-Week High
$57.67
Current Price
$52.99
52-Week Low
$27.22
$27.22$57.67
Current Yield
2.29%
Annual Dividend
$2.0445
Frequency
1x/year
Last Ex-Date
Dec 19, 2024
Dividend History
| Ex-Date | Amount | Pay Date |
|---|---|---|
| Dec 19, 2024 | $1.1735 | Dec 26, 2024 |
| Dec 21, 2023 | $0.0711 | Dec 27, 2023 |
| Dec 19, 2019 | $0.0158 | Dec 27, 2019 |
| Dec 20, 2018 | $0.7841 | Dec 27, 2018 |
| Dec 21, 2017 | $0.5795 | Dec 28, 2017 |
Dividend Payments Over Time
Category Comparison
| Metric | SBIO | Healthcare(212 ETFs) | Healthcare(24 ETFs) |
|---|---|---|---|
| Fund Info | |||
| Expense Ratio | 0.50% | 0.61% | 0.48% |
| AUM | $153.6M | $1.20B | $625.2M |
| Dividend Yield | 2.29% | 3.25% | 1.61% |
| Avg Volume | 50.9K | 339.2K | 80.5K |
| Holdings | 103 | 181 | 137 |
| Performance | |||
| 1-Month Return | +10.71% | +7.61% | +4.87% |
| 6-Month Return | +26.02% | +4.67% | +2.58% |
| YTD Return | +4.53% | +1.95% | -1.12% |
| 1-Year Return | +88.32% | +27.17% | +19.43% |
Compare with Another ETF
Search for an ETF to compare with SBIO:
FREE DOWNLOAD
The Beginner's Guide to ETFs
20 pages. Zero fluff. Everything you need to start investing in ETFs.
No spam. Unsubscribe anytime.